A detailed history of Vanguard Personalized Indexing Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vanguard Personalized Indexing Management, LLC holds 8,738 shares of NBIX stock, worth $1.22 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
8,738
Previous 10,855 19.5%
Holding current value
$1.22 Million
Previous $1.43 Million 15.73%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$130.4 - $143.74 $276,056 - $304,297
-2,117 Reduced 19.5%
8,738 $1.21 Million
Q4 2023

Feb 07, 2024

SELL
$106.07 - $132.76 $238,975 - $299,108
-2,253 Reduced 17.19%
10,855 $1.43 Million
Q3 2023

Nov 08, 2023

BUY
$94.02 - $117.1 $73,899 - $92,040
786 Added 6.38%
13,108 $1.47 Million
Q2 2023

Jul 28, 2023

BUY
$89.53 - $104.87 $18,264 - $21,393
204 Added 1.68%
12,322 $1.16 Million
Q1 2023

May 10, 2023

BUY
$94.11 - $123.02 $42,631 - $55,728
453 Added 3.88%
12,118 $1.23 Million
Q4 2022

Feb 10, 2023

BUY
$106.72 - $127.06 $53,573 - $63,784
502 Added 4.5%
11,665 $1.39 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $12,884 - $15,093
-140 Reduced 1.24%
11,163 $1.19 Million
Q2 2022

Aug 09, 2022

BUY
$75.79 - $100.07 $10,837 - $14,310
143 Added 1.28%
11,303 $1.1 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $808,542 - $1.06 Million
11,160 New
11,160 $1.05 Million
Q4 2021

Feb 23, 2022

SELL
$79.65 - $106.22 $265,473 - $354,031
-3,333 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$86.18 - $99.03 $293,098 - $336,801
-3,401 Reduced 50.5%
3,333 $320,000
Q2 2021

Aug 11, 2021

BUY
$89.43 - $102.27 $602,221 - $688,686
6,734 New
6,734 $655,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.3B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Vanguard Personalized Indexing Management, LLC Portfolio

Follow Vanguard Personalized Indexing Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Personalized Indexing Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Personalized Indexing Management, LLC with notifications on news.